Novel substituted pyrazolo [1, 5-a] pyrimidine compound and preparation method and application thereof
A 5-a, pyrazolo technology, applied in the direction of organic chemistry, drug combination, pharmaceutical formula, etc., can solve the problem of low oral bioavailability, large toxic and side effects, unsatisfactory clinical treatment effect and pharmacokinetic parameters, etc. question
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 1
[0092] Example 1: N-{3-fluoro-4-[6-methoxy-7-(3-morpholine propoxy)quinoline-4-oxyl]phenyl}-7-phenylpyrazolo Synthesis of [1,5-a]pyrimidine-5-carboxamide (Compound 1)
[0093]
[0094] Step 1: Synthesis of ethyl 4-phenyl-2,4-dioxobutanoate
[0095]
[0096] Metal sodium particles (11.5 g, 0.50 mol) were added in batches to 400 mL of cooled ethanol, and the reaction was stirred until the sodium particles disappeared, and then warmed to room temperature. Diethyl oxalate (36.5 g, 0.25 mol) and acetophenone (30.0 g, 0.25 mol) were added to the above solution, and the temperature was raised to 70° C., stirred for 5 h, most of the ethanol was removed by evaporation under reduced pressure, and the residue was added to 500 mL of water. . Ethyl acetate was extracted twice, 200 mL each time, and the ethyl acetate phase was discarded. The aqueous phase was adjusted to pH 4 with concentrated hydrochloric acid, extracted three times with ethyl acetate, 150 mL each time, combined t...
Embodiment 2
[0131] Example 2: N-{3-fluoro-4-[6-methoxy-7-(3-morpholine propoxy)quinoline-4-oxyl]phenyl}-7-(4-fluorobenzene base) pyrazolo[1,5-a]pyrimidine-5-carboxamide (compound 2)
[0132]
[0133] 1 H NMR (400MHz, CDCl 3 )δ9.94(s, 1H), 8.50(d, J=5.2Hz, 1H), 8.31(d, J=2.2Hz, 1H), 8.21(dd, J=8.6, 5.3Hz, 2H), 8.02( dd,J=11.9,2.0Hz,1H),7.90(s,1H),7.64–7.50(m,2H),7.44(s,1H),7.34–7.27(m,3H),6.94(d,J= 2.2Hz, 1H), 6.44(d, J=5.1Hz, 1H), 4.28(t, J=6.6Hz, 2H), 4.04(s, 3H), 3.78–3.66(m, 4H), 2.58(t, J=7.1Hz, 2H), 2.48(s, 4H), 2.25–2.01(m, 2H); MS(ESI) m / z(%): 667.2[M+H] + .
Embodiment 3
[0134] Example 3: N-{3-fluoro-4-[6-methoxy-7-(3-morpholine propoxy)quinoline-4-oxyl]phenyl}-7-(2-fluorobenzene base) pyrazolo[1,5-a]pyrimidine-5-carboxamide (compound 3)
[0135]
[0136] 1 H NMR (400MHz, CDCl 3 )δ9.91(s, 1H), 8.48(d, J=5.3Hz, 1H), 8.27(d, J=2.4Hz, 1H), 8.00(dd, J=11.9, 2.4Hz, 1H), 7.88( s,1H),7.83–7.75(m,1H),7.66–7.47(m,3H),7.42(s,1H),7.40–7.25(m,3H),6.93(d,J=2.4Hz,1H) ,6.43(d,J=4.9Hz,1H),4.26(t,J=6.7Hz,2H),4.02(s,3H),3.78–3.61(m,4H),2.60–2.40(m,6H), 2.19–2.05(m,2H); MS(ESI)m / z(%):667.7[M+H] + .
PUM
Abstract
Description
Claims
Application Information
- R&D Engineer
- R&D Manager
- IP Professional
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com